ZA200400143B - Improved chelator conjugates. - Google Patents
Improved chelator conjugates.Info
- Publication number
- ZA200400143B ZA200400143B ZA200400143A ZA200400143A ZA200400143B ZA 200400143 B ZA200400143 B ZA 200400143B ZA 200400143 A ZA200400143 A ZA 200400143A ZA 200400143 A ZA200400143 A ZA 200400143A ZA 200400143 B ZA200400143 B ZA 200400143B
- Authority
- ZA
- South Africa
- Prior art keywords
- chelator conjugates
- improved
- improved chelator
- radiometal
- conjugates
- Prior art date
Links
- 239000002738 chelating agent Substances 0.000 title abstract 2
- 239000002184 metal Substances 0.000 abstract 1
- 239000012217 radiopharmaceutical Substances 0.000 abstract 1
- 229940121896 radiopharmaceutical Drugs 0.000 abstract 1
- 230000002799 radiopharmaceutical effect Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Optics & Photonics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0116815.2A GB0116815D0 (en) | 2001-07-10 | 2001-07-10 | Improved chelator conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200400143B true ZA200400143B (en) | 2004-12-29 |
Family
ID=9918227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200400143A ZA200400143B (en) | 2001-07-10 | 2004-01-08 | Improved chelator conjugates. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7597875B2 (https=) |
| EP (1) | EP1404377B1 (https=) |
| JP (1) | JP5015409B2 (https=) |
| KR (1) | KR100892009B1 (https=) |
| CN (4) | CN101538313A (https=) |
| AT (1) | ATE304866T1 (https=) |
| AU (1) | AU2002317317B2 (https=) |
| BR (1) | BR0210965A (https=) |
| CA (1) | CA2450690C (https=) |
| DE (1) | DE60206272T2 (https=) |
| DK (1) | DK1404377T3 (https=) |
| ES (1) | ES2250671T3 (https=) |
| GB (1) | GB0116815D0 (https=) |
| HU (1) | HU228850B1 (https=) |
| IL (1) | IL159388A0 (https=) |
| MX (1) | MXPA04000210A (https=) |
| NO (1) | NO334093B1 (https=) |
| RU (1) | RU2298012C2 (https=) |
| WO (1) | WO2003006070A2 (https=) |
| ZA (1) | ZA200400143B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002054088A2 (en) | 2001-01-05 | 2002-07-11 | Duke University | Contrast enhancement agent for magnetic resonance imaging |
| BRPI0210886B8 (pt) * | 2001-07-10 | 2021-05-25 | Amersham Health As | composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal |
| NO20030115D0 (no) * | 2003-01-09 | 2003-01-09 | Amersham Health As | Kontrastmiddel |
| GB0416062D0 (en) * | 2004-07-19 | 2004-08-18 | Amersham Plc | Improved N4 chelator conjugates |
| WO2005044313A2 (en) * | 2003-11-06 | 2005-05-19 | Amersham Health As | Conjugates of angiotensin ii and an imaging moiety |
| JP2007512321A (ja) * | 2003-11-24 | 2007-05-17 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | 造影剤 |
| ATE447417T1 (de) * | 2004-03-04 | 2009-11-15 | Ge Healthcare As | Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie |
| DE602005025911D1 (de) | 2004-11-22 | 2011-02-24 | Ge Healthcare As | Kontrastmittel für eine extrazelluläre matrix |
| GB0427392D0 (en) * | 2004-12-15 | 2005-01-19 | Amersham Plc | Stabilised 99mTc compositions |
| ES2380680T3 (es) * | 2005-06-08 | 2012-05-17 | Ge Healthcare Limited | Procedimiento de uso de monóxido de carbono [11C] en la síntesis de marcaje interno de ésteres marcados con 11C mediante carbonilación fotoinducida de radicales libres sensitizados |
| GB0515974D0 (en) * | 2005-08-03 | 2005-09-07 | Ge Healthcare Ltd | Compounds and imaging methods |
| EP1989179B1 (en) | 2006-02-15 | 2011-01-26 | Ge Healthcare As | Contrast agents |
| US7943117B2 (en) * | 2006-06-08 | 2011-05-17 | Atomic Energy Council—Institute of Nuclear Research | Method for testing radiochemical purity of Tc-99m-TRODAT-1 |
| WO2008072973A2 (en) * | 2006-12-11 | 2008-06-19 | Ge Healthcare As | Radiolabelled peptide based compounds and uses thereof |
| EP2370447B1 (en) | 2008-12-02 | 2016-07-27 | The University of Melbourne | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals |
| GB0922014D0 (en) | 2009-12-17 | 2010-02-03 | Ge Healthcare Ltd | Novel integrin binders |
| DK2598175T3 (da) * | 2010-07-27 | 2020-08-03 | Serac Healthcare Ltd | Radiofarmaceutiske sammensætninger |
| GB201103696D0 (en) * | 2011-03-04 | 2011-04-20 | Ge Healthcare Ltd | Technetium labelled peptides |
| GB201110767D0 (en) | 2011-06-24 | 2011-08-10 | Ge Healthcare Ltd | Infection imaging |
| US20130195756A1 (en) | 2012-01-31 | 2013-08-01 | General Electric Company | 99mTc IMAGING AGENTS AND METHODS OF USE |
| CA2901231C (en) * | 2013-02-15 | 2020-06-23 | Thomas Jefferson University | Kit comprising lyophilized compositions for tumor imaging |
| GB201314936D0 (en) | 2013-08-21 | 2013-10-02 | Ge Healthcare Ltd | Radiolabelling method |
| GB201322456D0 (en) | 2013-12-18 | 2014-02-05 | Ge Healthcare Ltd | Radiotracer compositions and methods |
| EP3131585B1 (en) | 2014-03-19 | 2020-07-15 | Universität Zürich | Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy |
| US11584935B2 (en) | 2018-05-08 | 2023-02-21 | University Of Miami | Materials and methods for the delivery of therapeutic nucleic acids to tissues |
| US11844846B2 (en) | 2018-05-16 | 2023-12-19 | Emory University | Styrylbenzothiazole derivatives and uses in imaging methods |
| CN111548275A (zh) * | 2020-05-27 | 2020-08-18 | 龙曦宁（上海）医药科技有限公司 | 一种2-（氨基甲基）-n1,n1-二甲基丙烷-1,3-二胺三盐酸盐的合成方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1588978A (en) * | 1977-07-19 | 1981-05-07 | Ici Ltd | Coating processes |
| DE3930674A1 (de) * | 1989-09-11 | 1991-03-21 | Diagnostikforschung Inst | Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie |
| US5849261A (en) * | 1991-02-08 | 1998-12-15 | Diatide, Inc. | Radiolabeled vasoactive intestinal peptides for diagnosis and therapy |
| US5808091A (en) * | 1991-10-29 | 1998-09-15 | Bracco International B.V. | Rhenium and technetium complexes containing a hypoxia localizing moiety |
| CA2168652A1 (en) * | 1993-08-04 | 1995-02-16 | Colin Mill Archer | Radiometal complexes that localise in hypoxic tissue |
| CA2179990A1 (en) * | 1994-01-12 | 1995-07-20 | Gary Robert Bower | Biological targeting agents |
| ES2114735T3 (es) * | 1994-01-12 | 1998-06-01 | Bracco Int Bv | Ligandos y complejos metalicos de los mismos. |
| CA2332277A1 (en) | 1998-05-15 | 1999-11-25 | Nycomed Amersham Plc | Labelled glutamine and lysine analogues |
| US6783711B2 (en) * | 2000-05-23 | 2004-08-31 | Ge Osmonics, Inc. | Process for preparing a sulfonamide polymer matrix |
| WO2002072718A1 (en) | 2001-03-08 | 2002-09-19 | Matsushita Electric Industrial Co., Ltd. | Inkjet recording ink, method for producing said ink, and ink cartridge and recording device having said ink |
-
2001
- 2001-07-10 GB GBGB0116815.2A patent/GB0116815D0/en not_active Ceased
-
2002
- 2002-07-08 CN CNA2008102133680A patent/CN101538313A/zh active Pending
- 2002-07-08 CN CNA200910127855XA patent/CN101537190A/zh active Pending
- 2002-07-10 ES ES02745600T patent/ES2250671T3/es not_active Expired - Lifetime
- 2002-07-10 IL IL15938802A patent/IL159388A0/xx unknown
- 2002-07-10 DE DE60206272T patent/DE60206272T2/de not_active Expired - Lifetime
- 2002-07-10 US US10/483,455 patent/US7597875B2/en not_active Expired - Lifetime
- 2002-07-10 HU HU0401265A patent/HU228850B1/hu not_active IP Right Cessation
- 2002-07-10 AT AT02745600T patent/ATE304866T1/de active
- 2002-07-10 MX MXPA04000210A patent/MXPA04000210A/es active IP Right Grant
- 2002-07-10 BR BR0210965-4A patent/BR0210965A/pt active Search and Examination
- 2002-07-10 CN CN2009102035216A patent/CN101607913B/zh not_active Expired - Fee Related
- 2002-07-10 RU RU2003137592/04A patent/RU2298012C2/ru not_active IP Right Cessation
- 2002-07-10 EP EP02745600A patent/EP1404377B1/en not_active Expired - Lifetime
- 2002-07-10 CN CNB028140087A patent/CN100509061C/zh not_active Expired - Fee Related
- 2002-07-10 WO PCT/GB2002/003168 patent/WO2003006070A2/en not_active Ceased
- 2002-07-10 AU AU2002317317A patent/AU2002317317B2/en not_active Ceased
- 2002-07-10 JP JP2003511875A patent/JP5015409B2/ja not_active Expired - Lifetime
- 2002-07-10 KR KR1020047000303A patent/KR100892009B1/ko not_active Expired - Fee Related
- 2002-07-10 DK DK02745600T patent/DK1404377T3/da active
- 2002-07-10 CA CA002450690A patent/CA2450690C/en not_active Expired - Lifetime
-
2003
- 2003-12-16 NO NO20035597A patent/NO334093B1/no not_active IP Right Cessation
-
2004
- 2004-01-08 ZA ZA200400143A patent/ZA200400143B/xx unknown
-
2009
- 2009-10-01 US US12/571,508 patent/US8852550B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL159388A0 (en) | Improved chelator conjugates | |
| YU27403A (sh) | Postupak za pripremanje preparata u obliku praha | |
| IL181529A (en) | A method for radiofluorination, a compound containing radioactive fluorine and its use in the preparation of a radioactive drug | |
| MXPA03006093A (es) | Derivados de n(fenilsulfonil)glicina y su uso terapeutico. | |
| PL369530A1 (en) | Chemical compounds | |
| MA30153B1 (fr) | Anticorps anti-ox40l et methodes correspondantes | |
| SG147286A1 (en) | Manufacture of polyglumate-therapeutic agent conjugates | |
| TWI268278B (en) | 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses | |
| TW200716605A (en) | 2,6-quinolinyl derivatives, processes for preparing them and their uses | |
| DE60210598D1 (de) | 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA | |
| ZA200307365B (en) | Antibodies specific for CD44V6. | |
| GB0105224D0 (en) | Improved peptide-chelate conjugates | |
| DE60322562D1 (de) | Konjugate von tc komplexen und zielgerichtete einheiten und ihre verwendung in nmr-diagnostik | |
| PL1831239T3 (pl) | Sposób wytwarzania gamma-laktonu kwasu 17-hydroksy-6 beta, 7 beta,15 beta, 16 beta-bismetyleno-17 alpha-pregn-4-en-3-ono-21-karboksylowego i związki pośrednie kluczowe dla tego sposobu | |
| PL352104A1 (en) | Oral composition containing perlite | |
| DE60213084D1 (de) | 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA | |
| TW200732345A (en) | Niobium compound | |
| ATE242763T1 (de) | Methoximinophenylessigsäureamide | |
| MXPA05008108A (es) | Exo-(2r)(+))-2-amino-7-azabiciclo[2.2.1]heptan-7-carboxilato de terc-butilo, compuestos intermedios y procedimiento para prepararlos y aislarlos. | |
| WO2004075028A3 (en) | Systems and methods for variable rebate and incentive programs | |
| NO20021429D0 (no) | 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner | |
| MXPA04002104A (es) | Anticuerpos contra caspasa-8, su preparacion y uso. | |
| ITMI20030827A1 (it) | Composizione farmaceutica contenente l'associazione levodopa/carbidopa. | |
| TW200407314A (en) | Preparation of 4, 6-dichloro-5-fluoropyrimidine | |
| ES2183543T3 (es) | Derivado de tiocolchicosida, su preparacion y su aplicacion en terapeutica. |